



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/818,918	03/27/2001	Arthur M. Krieg	C1039/7048 (AWS)	4953

23628 7590 05/04/2004

WOLF GREENFIELD & SACKS, PC
FEDERAL RESERVE PLAZA
600 ATLANTIC AVENUE
BOSTON, MA 02210-2211

EXAMINER

ZARA, JANE J

ART UNIT	PAPER NUMBER
----------	--------------

1635

DATE MAILED: 05/04/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Interview Summary

Application No.

09/818,918

Applicant(s)

KRIEG ET AL.

Examiner

Jane Zara

Art Unit

1635

All participants (applicant, applicant's representative, PTO personnel):

(1) Jane Zara. (3)_____.

(2) Alan Steele. (4)_____.

Date of Interview: about 4-10-04.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.

If Yes, brief description: _____.

Claim(s) discussed: all pending.

Identification of prior art discussed: _____.


Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☒ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See attachment.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

Attachment

The outstanding enablement rejection was discussed for the scope of the claimed invention drawn to methods of treating an atopic condition comprising administration of any CpG containing oligonucleotide, wherein C is unmethylated. Atopic conditions read on various conditions, including asthma, dermatitis, allergies including hayfever. The instant disclosure teaches the treatment of the atopic conditions dermatitis and asthma comprising the administration of SEQ ID NO: 10. The instant disclosure also teaches increases in a TH1 immune response (e.g. increased expression of IL6) in vitro using mouse and human cells, where optimal CpG containing sequences varied between mice and human cells in their ability to induce a TH1 response response. No correlation is taught in the instant disclosure between the ability of these CpG containing oligonucleotides to induce a TH1 response in vitro (e.g. amount of IL6 induction) and their ability to treat a representative number of atopic conditions in vivo. The instant invention is not enabled for the broad scope claimed.